<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324060</url>
  </required_header>
  <id_info>
    <org_study_id>TPO</org_study_id>
    <nct_id>NCT04324060</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia</brief_title>
  <official_title>A Randomized Trial of Recombinant Human Thrombopoietin Versus Placebo for Low/Intermediate-1 Risk Myelodysplastic Syndromes With Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndrome (MDS) is a kind of clonal myeloid tumor. The major manifestation is&#xD;
      decrease of tri-lineages of blood due to ineffective and abnormal hematopoiesis, some of&#xD;
      which can progress to acute myeloid leukemia. According to the international prognosis&#xD;
      scoring system (IPSS) of MDS, about 10% low/intermediate risk-1 MDS patients have severe&#xD;
      thrombocytopenia (PLT &lt; 30 × 109/ L). These patients have both decreased platelet count and&#xD;
      platelet dysfunction, resulting in a high risk of bleeding. In the new prognostic score, such&#xD;
      as IPSS-r, the degree of thrombocytopenia is regarded as a poor prognostic factor. Platelet&#xD;
      transfusion is mainly used in the treatment of this kind of patients. The indications of&#xD;
      transfusion include bleeding events or severe platelet count reduction (&lt; 10 × 109 / L).&#xD;
      However, platelet transfusion can only lead to short-term platelet elevation, while repeated&#xD;
      transfusion increases the possibility of infection and ineffective platelet transfusion. TPO&#xD;
      is a newly discovered hematopoietic promoting factor, which can specifically bind to the TPO&#xD;
      receptor on the cell and participate in the regulation of proliferation, differentiation,&#xD;
      maturation and division of megakaryocyte to form functional platelet. The efficacy and safety&#xD;
      of the TPO receptor agonists eltrombopag and romiplostim in the treatment of thrombocytopenia&#xD;
      in low/intermediate risk-1 MDS patients have been successfully confirmed in foreign studies.&#xD;
      Recombinant human thrombopoietin (rhTPO) is also a kind of a TPO receptor agonists which is&#xD;
      highly specific platelet stimulating factor. At present, there is no large report on the&#xD;
      application of rhTPO in such patients. The purpose of this study is to explore the short-term&#xD;
      and long-term therapeutic effect and safety of rhTPO on low/intermediate risk-1 MDS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>overall response rate of platelet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of side effects</measure>
    <time_frame>1 year</time_frame>
    <description>rate of all kinds of side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO bleeding score</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate frequency and severity of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of platelet transfusion</measure>
    <time_frame>1 year</time_frame>
    <description>the frequency and amount of platelet transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>onset time for overall response</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>onset time for complete and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of overall response</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>during time for complete and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of TPO antibody</measure>
    <time_frame>1 year</time_frame>
    <description>rate of presence of TPO antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality for MDS patients</measure>
    <time_frame>1 year</time_frame>
    <description>life quality for MDS patients by QoL-E questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the increased number of myeloblasts in bone marrow and peripheral blood</measure>
    <time_frame>1 year</time_frame>
    <description>the increased number of myeloblasts in bone marrow and peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of progression to high-risk MDS or leukemia</measure>
    <time_frame>1 year</time_frame>
    <description>incidence of progression to high-risk MDS or leukemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Low/Intermediate Risk-1 MDS</condition>
  <arm_group>
    <arm_group_label>TPO treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol + rhTPO (recombinant human thrombopoietin injection)</intervention_name>
    <description>subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased &gt;50×10e9/L, total course is 6 months</description>
    <arm_group_label>TPO treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol + sodium chloride</intervention_name>
    <description>Danazol 0.2g tid po+ control (sodium chloride)</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed MDS, IPSS low / intermediate risk-1&#xD;
&#xD;
          2. In the 4 weeks before inclusion, the average value of platelets was ≤ 30 × 10e9 / L,&#xD;
             or &lt; 50 × 10e9 / L with bleeding events&#xD;
&#xD;
          3. Patients with EPO due to anemia and G-CSF due to severe neutropenia can be included,&#xD;
             and the dosage will not change during trial&#xD;
&#xD;
          4. Baseline liver and kidney function: ALT / ASL within 3 times normal upper limit, TBIL&#xD;
             within 2 times normal upper limit, and creatinine within 2 times normal upper limit&#xD;
&#xD;
          5. ECOG 0-2 points&#xD;
&#xD;
          6. Able to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating&#xD;
&#xD;
          2. IPSS intermediate risk-2 / high risk MDS&#xD;
&#xD;
          3. More than 5% of myeloblasts in bone marrow&#xD;
&#xD;
          4. Myelofibrosis&#xD;
&#xD;
          5. Previous transplantation or ATG treatment within 6 months&#xD;
&#xD;
          6. Previous use of IL-11, TPO or other TPO receptor agonists&#xD;
&#xD;
          7. Active infection or tumor&#xD;
&#xD;
          8. Thromboembolic or hemorrhagic disease&#xD;
&#xD;
          9. Serious heart disease, including unstable angina, congestive heart failure,&#xD;
             arrhythmia, 1-year history of myocardial infarction&#xD;
&#xD;
         10. Intracranial hemorrhage within 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bing Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>protocol, consent form, clinical data would be available by personal contact</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>10 years</ipd_time_frame>
    <ipd_access_criteria>personal contact including emails</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

